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osting by EAbstract Migraine cannot be cured and the aim, shared with the patient, is to minimise the impact
of the illness on the patient’s life and lifestyle. The aim of prophylaxis is to reduce the number of
migraine attacks. Prophylaxis should be considered when appropriately used acute management
gives inadequate control of symptoms. The efﬁcacy and safety of topiramate 50 mg/d and thioctic
acid (a-lipoic acid) 300 mg/d either as monotherapy or in combination were investigated as
migraine prophylactic agents. Forty secondary school migraineur girls were enrolled in the study.
The study was conducted in two phases, a prospective baseline phase and 1-month treatment phase.
Combined topiramate/thioctic acid therapy was more effective than either topiramate or thioctic
acid monotherapy as a migraine-preventive treatment. Combined topiramate/thioctic acid therapy
decreased the mean monthly migraine frequency from 5.86 ± 1.2 to 2.6 ± 0.98 (p 6 0.05), topira-
mate (50 mg/d) from 5.71 ± 1.4 to 4.75 ± 1.5 and thioctic acid (300 mg/d) from 5.68 ± 1.6 to
5.22 ± 1.8. Reduction in mean monthly migraine days was also signiﬁcantly greater in the group
receiving combined topiramate/thioctic acid (from 12.32 ± 1.85 to 5.74 ± 1.1) compared to those
receiving either topiramate 50 mg/d (from 12.7 ± 1.34 to 11.85 ± 1.35) or thioctic acid 300 mg/d
(from 12.5 ± 1.72 to 11.65 ± 1.44). The responder rate (% of patients showing P50% reduction
in monthly migraine frequency) was 85% in patients receiving combined topiramate/thioctic acid
therapy compared to 30% and 20% in patients receiving either topiramate or thioctic acid, respec-
tively. The incidence of adverse events was higher in patients receiving topiramate (50 mg/d) mono-
therapy. The most common adverse events were nausea, fatigue, paraesthesia and taste perversion.o.com (A.M. Ali).
ity. All rights reserved. Peer-
d University.
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240 A.M. Ali et al.We conclude that combined topiramate/thioctic acid therapy is more effective and better tolerated
than topiramate monotherapy. The combination has lower monthly medication costs compared to
the traditionally used topiramate 100 mg monotherapy.
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Migraine is a recurrent headache disorder with intense pain
that may be unilateral and accompanied by nausea or vomiting
as well as photosensitivity and phonosensitivity. The incidence
of migraine headache is claimed to be 25% in women and 8%
in men. Migraine also affects about 5–10% of children and
adolescents (Carolyn et al., 2009). Approximately 53% of pa-
tients with severe migraine report that their attacks require bed
rest or are a source of severe impairment (Lipton et al., 2001).
The cost of missed workdays and impaired performance be-
cause of migraine is estimated at $18 billions (Silberstein
et al., 2002) in the USA.
The exact cause of migraine headache is still unknown.
Current research suggests that inﬂammation in the blood ves-
sels of the brain causes them to swell and press on nearby
nerves, causing pain (Salomone et al., 2009). This inﬂamma-
tion may arise in or be stimulated by signals from the trigem-
inal nerve, the main sensory nerve of the face (Debruyne and
Herroelen, 2009). The role of oxidative stress in the pathogen-
esis of migraine was supported by the ﬁndings of various stud-
ies. A signiﬁcant increase in plasma levels of thiobarbituric
acid reacting substances (TBARS) has been reported in migrai-
neurs (Tozzi-Ciancarelli et al., 1997; Tuncel et al., 2008).
Changes in platelet superoxide dismutase (SOD) activity have
been reported in patients having migraine with aura (Shimom-
ura et al., 1994). One study has reported a signiﬁcant increase
in urinary nitric oxide metabolites and lipid peroxidation by-
products in migraineurs (Cinancarelli et al., 2003). Signiﬁcant
reductions in erythrocytic glutathione peroxidase (GSH-Px)
and SOD activities have been reported in migraineurs with
and without aura (Bolayir et al., 2004).
The United States Headache Consortium recommends pre-
ventive treatment when the following occurs: (a) migraine sig-
niﬁcantly interferes with daily routine, despite acute treatment;
(b) acute medications fail, are contraindicated or lead to trou-
blesome adverse events; (c) acute medications are overused; (d)
there are circumstances, such as hemiplegic migraine or risk of
permanent neurologic injury; (e) the patient experiences
frequent headache attacks (>2 per week); or (f) the patient
prefers preventive treatment (Silberstein, 2000). Effective pre-
ventive migraine treatments include antiepileptic drugs (Vikelis
and Rapoport, 2010), antidepressants (Nagata, 2009; Koch
and Ju¨rgens, 2009), b-adrenoceptor blockers (Evers et al.,
2006, 2009), calcium channel blockers (Negoro, 2009), botu-
linum toxin (Taylor, 2008; Mathew and Jaffri, 2009) and
surgery (Guyuron et al., 2009). The antiepileptic drug ‘‘topira-
mate’’ is approved for the prophylaxis of migraine headache in
adults. Topiramate, at doses of 100 and 200 mg/d (but not
50 mg/d), had been reported to be effective as a migraine-pre-
ventive therapy (Silberstein et al., 2004). Thioctic (a-lipoic)
acid is both water- and fat-soluble antioxidant that is directly
(by removing reactive species) and indirectly (by chelating tran-
sition metal ions) involved in the protection of biological com-
ponents from the damage of oxidative stress (Haenen andBast, 1991; Coon et al., 2003; Packer et al., 1996; Cronan
et al., 2005). The use of thioctic acid in migraine prevention
has been reported by some investigators (Sun-Edelstein and
Mauskop, 2009). This study evaluated the efﬁcacy and safety
of topiramate 50 mg/d, thioctic acid 300 mg/d or a combina-
tion of both in migraine prophylaxis. The Egyptian MOH reg-
istration number for Topamax is 21628. The MOH
registration number for Thiotacid is 20943. Topamax is indi-
cated for migraine prophylaxis and as initial monotherapy in
patients 10 years of age and older with partial onset or primary
generalized tonic–clonic seizures. Thiotacid is indicated for the
treatment of diabetic polyneuropathy, neuritis, poly-neuritis,
optic neuritis and encephalopathies.2. Methods
2.1. Study design
The study subjects were entered into a prospective 1-month
baseline phase and headache records were reviewed. Baseline
phase completers who met the study criteria were randomized
to either topiramate 50 mg/d, thioctic acid 300 mg/d or a com-
bination of both. Topiramate dose was titrated by 25 mg/week
to the assigned dose. During the maintenance period, topira-
mate 50 mg was given in two divided doses (morning and even-
ing), while thioctic acid 300 mg was given on a once daily basis
in the morning. All treatments were continued for 1 month.
During the treatment period, school clinic visits were
planned weekly. Headache, medication and adverse reaction
records were collected and analyzed and new records were dis-
pensed. To ensure better compliance, the study medications
were reﬁlled freely every week (7 doses per regimen). Subjects
were allowed to take acute migraine mediations (including
aspirin, paracetamol, NSAIDs, triptans and ergot derivatives)
recording the name and amount of the medication used.
2.1.1. Patients
Forty secondary school girls with P3-month International
Headache Society (IHS) migraine history were enrolled in this
randomized open-label efﬁcacy study. Patients were random-
ized to either topiramate 50 mg/d, thioctic acid 300 mg/d or
a combination of both. All drug regimens were continued for
1 month.
2.1.2. Setting
Out-patient treatment at secondary school Health Insurance
Clinics, Cairo, Egypt.
2.1.3. Inclusion criteria
Secondary school girl migraineurs aged 16–20 years experi-
enced 5–11 migraines and 10–14 migraine days during the pro-
spective 1-month baseline phase. All patients should fulﬁl the
IHS diagnostic criteria for migraine headache (International
Headache Society Clinical Trials Subcommittee, 2000).
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Figure 1 Mean monthly migraine frequency in migraineur
school girls treated with either topiramate (50 mg/d) or thioctic
acid (300 mg/d) or a combination of both. *Signiﬁcantly different
from baseline at p 6 0.05, paired student t-test.
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Patients with headaches other than migraine, previous treat-
ment with any migraine prophylactic agent in the preceding
3 months, daily use of NSAIDs or corticosteroids and previous
treatment with any of the test drugs in the preceding 3 months.
2.1.5. Study drugs
Topiramate (Topamax), Janssen-Cilag, thioctic acid (Thiot-
acid), EvaPharma, Egypt.
2.2. Efﬁcacy measures
Reduction in mean monthly migraine frequency and mean
monthly migraine days from baseline was determined for the
study groups. Patients were directed to record the start and
end of migraine attacks. Migraine frequency was assessed by
counting migraine headache that started, terminated or reap-
peared within 24 h. If the attack is continued for longer than
24 h, it was counted as a new migraine attack. The responder
rate (P50% reduction in monthly migraine frequency) or per-
centage of migraineurs responding to treatment was also
determined.
2.3. Safety measures
Safety was assessed by the incidence of adverse drug reactions
(ADRs) and clinical examination. Clinical examination and
ADRs were evaluated at weekly intervals.
2.4. Data analysis
Data were expressed as mean ± standard deviation. A paired
student t-test was used to determine the difference between
means of the same group at baseline and after drug therapy.
The level of signiﬁcance was set at p 6 0.05.
3. Results
3.1. Efﬁcacy measures
The mean change from baseline in monthly migraine frequency
(Table 1 and Fig. 1) was signiﬁcantly greater for patients
receiving combined topiramate/thioctic acid therapy (group
3) but not for those receiving either topiramate 50 mg/d or thi-
octic acid 300 mg/d monotherapies (groups 1 and 2, respec-
tively). Combined topiramate/thioctic acid therapy decreased
the mean monthly migraine frequency from 5.86 ± 1.2 to
2.6 ± 0.98 (p 6 0.05), topiramate (50 mg/d) from 5.71 ± 1.4
to 4.75 ± 1.5 and thioctic acid (300 mg/d) from 5.68 ± 1.6
to 5.22 ± 1.8.Table 1 Demographic, baseline, and post-treatment data.a
Groups Age (years) BMI (kg/m2) Mean monthly migraine
frequency
Baseline Post-trea
1 (n= 10) 17.6 ± 1.5 22.36 ± 0.66 5.71 ± 1.4 4.75 ± 1
2 (n= 10) 17.8 ± 1.4 23.14 ± 0.45 5.68 ± 1.6 5.22 ± 1
3 (n= 20) 17.4 ± 1.7 23 ± 0.73 5.86 ± 1.2 2.6 ± 0.
a Data are given as mean ± SD following 2-month therapy.The mean change from baseline in monthly migraine days
(Table 1 and Fig. 2) was signiﬁcantly greater for patients
receiving combined topiramate/thioctic acid therapy but not
for those receiving either topiramate 50 mg/d or thioctic acid
300 mg/d monotherapies. Combined topiramate/thioctic acid
therapy decreased the mean monthly migraine days from
12.32 ± 1.85 to 5.74 ± 1.25 (p 6 0.05), topiramate (50 mg/d)
from 12.7 ± 1.34 to 11.85 ± 1.35 and thioctic acid (300 mg/
d) from 12.5 ± 1.72 to 11.65 ± 1.44.
The responder rates (Table 1 and Fig. 3) were 30%, 20%
and 85% for groups 1, 2 and 3, respectively. The responder
rate is the percentage of patients showing P50% reduction
in monthly migraine frequency in each group.
3.2. Safety measures
The most common ADRs observed are listed in Table 2. High-
er incidence of ADRs mainly nausea (20%), fatigue (20%) par-
aesthesia (10%) and taste perversion (10%) was noted in
patients receiving topiramate (50 mg/d) monotherapy.
4. Discussion
Many antiepileptic drugs (AEDs) are increasingly recom-
mended for migraine prophylaxis because of many placebo-
controlled double-blind trials that prove them effective
(Silberstein, 2000). Other controlled clinical studies (Mathew
et al., 1995; Klapper, 1997; Freitag et al., 2002) had examined
the efﬁcacy of AEDs in migraine prophylaxis. Divalproex so-
dium had a responder rate of 48% (Mathew et al., 1995),
44% (Klapper, 1997), and 41% (Freitag et al., 2002) in three
placebo-controlled trials. Gabapentin had a responder rateMean monthly migraine days Responder rate (%)
tment Baseline Post-treatment
.5 12.7 ± 1.34 11.85 ± 1.35 30
.8 12.5 ± 1.72 11.65 ± 1.44 20
98 12.32 ± 1.85 5.74 ± 1.25 85
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Figure 2 Mean monthly migraine days in migraineur school girls
treated with either to piramate (50 mg/d), thioctic acid (300 mg/d)
or a combination of both. *Signiﬁcantly different from baseline at
p 6 0.05, paired student t-test.
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Figure 3 Responder rate (% of patients showing P50%
reduction in monthly migraine frequency) in migraineur school
girls treated with either topiramate (50 mg/d), thioctic acid
(300 mg/d) or a combination of both.
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1999). These studies support the clinical value of AEDs for mi-
graine prevention.
A number of clinical studies had also proven the efﬁcacy of
TCAs (Couch and Hassanein, 1979) and beta-adrenoceptor
blockers (Tfelt-Hansen et al., 1984) in migraine prophylaxis.
The efﬁcacy and safety of topiramate therapy as a mi-
graine-preventive agent had been proved in many placebo-con-
trolled double-blind trials (Diener et al., 2007; Silberstein et al.,
2004, 2009). In a large, controlled trial (MIGR-001Study),
topiramate at doses of 100 and 200 mg/d signiﬁcantly reduced
monthly migraine frequency and monthly migraine days but
not topiramate 50 mg/d (Silberstein et al., 2004). The same
trial concluded that topiramate 100 and 200 mg/d had respon-Table 2 Treatment-associated adverse reactions.
Groups Nausea Fatigue Paraesthesia Taste perversion
1 (n= 10) 2 2 1 1
2 (n= 10) 1 0 0 0
3 (n= 20) 1 1 0 0der rates of 54% and 52.3%, respectively, compared for pla-
cebo (Silberstein et al., 2004). The efﬁcacy of topiramate in
the prevention of migraine headache may be related to restor-
ing the balance between the excitatory glutamate-mediated
transmission and inhibitory GABA-mediated transmission in
cerebral tissues, mainly in speciﬁc brain areas (Hamada, 2009).
One randomized double-blind placebo-controlled trial (Ma-
gis et al., 2007) supports the clinical utility of thioctic acid
(600 mg/d) for migraine prevention. Impaired mitochondrial
phosphorylation potential had been implicated in migraine
pathogenesis (Magis et al., 2007). The migraine-preventive ef-
fect of thioctic acid may be related to its antioxidant (Cronan
et al., 2005) and mitochondrial bioenergetic (Magis et al.,
2007) properties. Thioctic acid had been used clinically over
many years with a good tolerability and safety record (Cremer
et al., 2006).
5. Conclusion
In this randomized open-label study, combined topiramate
(50 mg/d) and thioctic acid (300 mg/d) therapy was more effec-
tive in reducing monthly migraine frequency and migraine
days with better responder rate compared with topiramate
(50 mg/d) or thioctic acid (300 mg/d) monotherapies. In addi-
tion to signiﬁcantly reducing mean monthly migraine fre-
quency and migraine headache days, treatment with this
combination was well tolerated and not associated with serious
adverse events. The most common adverse reactions were nau-
sea, fatigue and dysgeusia. Being more effective and better tol-
erated than topiramate monotherapy, we recommend the use
of this combination in migraine prophylaxis. In addition, this
combination has lower monthly medication costs compared to
the traditionally used topiramate 100 mg monotherapy.
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